The decline was in line with what the company preliminarily reported last month, reflecting much lower collaboration revenues than in the prior year period.
The company's life sciences segment had $1.08 billion in revenues, driven by strong performance of the preanalytical systems, diagnostic systems, and biosciences units.
The firm's diagnostics division was up 4 percent. Molecular diagnostics grew 7 percent, cytology & perinatal was flat, and blood screening was down 2 percent.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
